GOdyno will improve understanding of the progression of glioblastoma (GBM) by providing clinically relevant insights into how the interplay between GBM cells and their microenvironment drives treatment resistance, resulting in the identification and re-evaluation of therapeutic targets and raising new research questions in the field of cancer treatment.
This project is financed by the Slovenian Research and Innovation Agency (ARIS).
Project ID: ID: N3-0394
Duration: 1.1.2025 – 31.12.2026
